CEA and CA 19-9 combined tumor marker index as a prognostic tool for metastatic pancreatic cancer: is two better than one?

Basit Öğe Kaydı
dc.contributor.authorDemir, Bilgin
dc.contributor.authorAlemdar, Merve Biyikli
dc.contributor.authorBalcik, Onur Yazdan
dc.date.accessioned2026-01-24T12:26:48Z
dc.date.available2026-01-24T12:26:48Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractMetastatic pancreatic cancer (PC) is one of the cancers with the worst prognosis, and prognostic tests are lacking in this population. If an effective prognostic indicator can be identified, the patient population can be monitored more closely. This retrospective study aimed to investigate the prognostic impact of tumor marker index (TMI) in patients with metastatic PC. Patients diagnosed with metastatic PC at Ayd & imath;n Adnan Menderes University between 2019 and 2024 were included in the study. Demographic data, tumor marker levels, and treatment received were recorded. The prognostic value of TMI was determined as 3.15 using the receiver operating characteristic (ROC) method. Progression-free survival (PFS) and overall survival (OS) were recorded. 218 metastatic PC patients with a median follow-up duration of 10.81 months were included in the study. The median PFS was 7.26 months for the High TMI group, while it was 10.76 months for the Low TMI group (P=0.003). The median OS of patients with high TMI was 9.3 months, which was significantly lower than the 17.9 months observed in the low TMI group (P<0.001). TMI is a simple and, cost-effective prognostic tool for metastatic PC, and a higher TMI is associated with poorer survival outcomes.
dc.identifier.doi10.62347/JYAD4332
dc.identifier.endpage3569
dc.identifier.issn2156-6976
dc.identifier.issue8
dc.identifier.pmid40948514
dc.identifier.startpage3557
dc.identifier.urihttps://doi.org/10.62347/JYAD4332
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4946
dc.identifier.volume15
dc.identifier.wosWOS:001577059000011
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherE-Century Publishing Corp
dc.relation.ispartofAmerican Journal of Cancer Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectCarcinoembryonic antigen
dc.subjectcarbohydrate antigen 19-9
dc.subjecttumor marker index
dc.subjectmetastatic pancreatic cancer
dc.titleCEA and CA 19-9 combined tumor marker index as a prognostic tool for metastatic pancreatic cancer: is two better than one?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu